Type 2 Diabetes Mellitus Completed Phase 3 Trials for Insulin glargine (DB00047)

Also known as: Diabetes Mellitus Non-insulin-dependent / Type-2 Diabetes Mellitus / Diabetes Mellitus Type 2 (T2DM) / Diabetes Mellitus Type-2 / Type 2 Diabetes (T2DM) / Diabetes, Type 2 / Diabetes Mellitus, Type 2 (T2DM) / Diabetes Mellitus,Type 2 / Diabetes Type II / Type-II Diabetes Mellitus / Diabetes Mellitus 2 Type / T2DM / Diabetes Mellitus Type II / Type II Diabetes / Diabetes Mellitus, Type 2 / Type 2 Diabetes Mellitus (T2DM) / Diabetes Type Two / Diabetes Mellitus - Type 2 / Diabetes, Type II / Non-Insulin-Dependent Diabetes Mellitus / Diabetes Mellitus. Type 2 / Diabetes Type 2 / Type 2 Diabetes Mellitus (T2D) / Type 2 Diabetes (T2D) / Type II; Diabetes / Type II Diabetes Mellitus / Diabetes Mellitus, Type II / NIDDM / Type-2 Diabetes / Type 2 Diabetes Mellitus(T2DM) / Type 2 Diabetes / Type 2-diabetes / Noninsulin Dependent Diabetes Mellitus, Type II / Diabetes Mellitus Type 2 / Type Two Diabetes Mellitus / T2DM (Type 2 Diabetes Mellitus) / Type-2-diabetes Mellitus / Diabetes mellitus -adult onset / Diabetes mellitus non insulin-dep / Maturity onset diabetes / Diabetes mellitus maturity onset

IndicationStatusPhase
DBCOND0029752 (Type 2 Diabetes Mellitus)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01779375RISE Pediatric Medication StudyTreatment
NCT01755468Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Pilot Study)Treatment
NCT01621178A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)Treatment
NCT02227875Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)Treatment
NCT00360334A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes PatientsTreatment
NCT01768559Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic PatientsTreatment
NCT02058160Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 DiabetesTreatment
NCT02058147Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DMTreatment
NCT03214380A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 DiabetesTreatment
NCT02787551Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension PeriodTreatment
NCT01894568A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin TreatmentTreatment
NCT02738879Randomized Sitagliptin Withdrawal Study (MK-0431-845)Treatment
NCT02551874A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on MetforminTreatment
NCT01648582A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes MellitusTreatment
NCT02752412Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic DrugsTreatment
NCT01462266Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)Treatment
NCT01682759A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)Treatment
NCT01755156A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)Treatment
NCT02033889A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).Treatment
NCT02059187The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)Treatment
NCT02099110Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)Treatment
NCT02855684Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic TherapyTreatment
NCT02132637A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 DiabetesTreatment
NCT02294474Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin GlargineTreatment
NCT00032487Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)Treatment
NCT00097500Effects of Exenatide and Insulin Glargine in Subjects With Type 2 DiabetesTreatment
NCT00099619Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate TherapyTreatment
NCT00641056Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)Treatment
NCT00935532Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes MellitusTreatment
NCT0097528624-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin GlargineTreatment
NCT01499095Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic TherapyTreatment
NCT01499082Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime InsulinTreatment
NCT01584232A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes MellitusTreatment
NCT01676220Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic TherapyTreatment
NCT01689142Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes MellitusTreatment
NCT02168491Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal InsulinTreatment
NCT02320721Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic MedicationsTreatment
NCT02401243Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus PatientsTreatment
NCT02585674Comparison of MyStar DoseCoach to Routine Titration in Adult Patients With Type 2 Diabetes Mellitus Using ToujeoTreatment
NCT02752113Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 DiabetesTreatment
NCT02227212Ease of Use and Safety of the New U300 Pen Injector in Insulin-Naïve Patients With T2DMTreatment
NCT00755287A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.Treatment
NCT00551356Lispro Mix 25 vs. Glargine in Type 2 DiabeticsTreatment
NCT00355849Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 DiabetesTreatment
NCT02773368A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes MellitusTreatment
NCT01959529A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular EventsTreatment
NCT02501161A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes MellitusTreatment
NCT02128932Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 DiabetesTreatment
NCT03078478A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic DrugsTreatment
NCT02030600A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 DiabetesTreatment
NCT01819129Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 DiabetesTreatment
NCT01952145A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes MellitusTreatment
NCT02906917A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment IntensificationTreatment
NCT02229227Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes MellitusTreatment
NCT01582451A Study of LY2605541 in Participants With Type 2 Diabetes MellitusTreatment
NCT01468987A Study in Participants With Type 2 Diabetes MellitusTreatment
NCT00437112Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 DiabetesTreatment
NCT02420262A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes MellitusTreatment
NCT02302716A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes MellitusTreatment
NCT01076647Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 DiabetesTreatment
NCT00510952Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE)Treatment
NCT01068665Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 DiabetesTreatment
NCT01068678Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 DiabetesTreatment
NCT00560417Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and ExenatideTreatment
NCT00598793Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD TherapyTreatment
NCT01045707Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 DiabetesTreatment
NCT01045447Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 DiabetesTreatment
NCT01336751Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination TreatmentTreatment
NCT00783744Insulin Glargine Combination Therapies in Type II DiabeticsTreatment
NCT01421459A Study in Adults With Type 2 DiabetesTreatment
NCT01191268A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)Treatment
NCT00000620Action to Control Cardiovascular Risk in Diabetes (ACCORD)Prevention
NCT00851903Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension TrialTreatment
NCT00838916A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 DiabetesTreatment
NCT02152371A Study of Dulaglutide (LY2189265) in Participants With Type II DiabetesTreatment
NCT01570751A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose InsulinTreatment
NCT01272193Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 DiabetesTreatment
NCT00283751Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 DiabetesTreatment
NCT00331851Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 DiabetesTreatment
NCT00174668Insulin Glulisine in Diabetes Mellitus, Type 2Treatment
NCT00174642Opposing Step-by-step Insulin Reinforcement to Intensified StrategyTreatment
NCT00272064ELEONOR STUDY: Insulin Glulisine in Type 2 Diabetes Mellitus.Treatment
NCT00097877Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 DiabetesTreatment
NCT00097084Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 DiabetesTreatment
NCT00082381Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and MetforminTreatment
NCT01075282A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)Treatment
NCT00106366Comparison of Insulin Detemir With Insulin Glargine in Type 2 DiabetesTreatment
NCT00135057Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal InsulinTreatment
NCT00135096Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal InsulinTreatment
NCT00666718A Comparison Study of Basal Bolus Therapies Together With Lispro Insulin in Type 2 Diabetes PatientsTreatment
NCT00653341Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)Treatment
NCT01059799Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 DiabetesTreatment
NCT01849289A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 DiabetesTreatment
NCT01135992Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™)Treatment
NCT00976391A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin GlargineTreatment
NCT00972283Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 DiabetesTreatment
NCT00982644Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 DiabetesTreatment
NCT01006291Comparison of NN1250 With Insulin Glargine in Type 2 DiabetesTreatment
NCT00309244Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-upPrevention
NCT00151697LANN-study: Lantus, Amaryl, Novorapid, Novomix StudyTreatment
NCT0056322520 Week Bridging Study in Type II DMTreatment